Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30865655 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9295322 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| SCHEMBL6824874 | 0.82 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| SCHEMBL16418296 | 0.80 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| SCHEMBL8787263 | 0.78 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9294951 | 0.78 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9327988 | 0.78 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL9295429 | 0.78 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL9294700 | 0.76 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CMAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL9294956 | 0.75 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691859-B2 | Broad spectrum antibacterial compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-04-08 | — | — | US | claimed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | claimed |
| EP-1945209-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2008041966-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U.S. ARMY MEDICAL RESEARCH & MATERIEL COMMAND (US) | 2008-04-10 | — | — | WO | claimed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | claimed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | claimed |
| US-5354769-A | Treatment of anorexia | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1994-10-11 | — | — | US | claimed |
| US-5310930-A | Cyclization of the carboximidate salt | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 1994-05-10 | — | — | US | claimed |
| JP-5271223-A | — | — | None | — | — | JP | disclosed |
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-8691859-B2 | Broad spectrum antibacterial compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2207801-B1 | METHODS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8207209-B2 | Methods of inhibiting viral infection | FUNCTIONAL GENETICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-0257171-A1 | (Benzofuran-2-yl)imidazoles having pharmaceutical activity, their salts and relevant production processes | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1988-03-02 | — | — | EP | disclosed |
| EP-0257171-A1 | (Benzofuran-2-yl)imidazoles having pharmaceutical activity, their salts and relevant production processes | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1988-03-02 | — | — | EP | disclosed |
| US-4452986-A | THROMBOXANE A2 SYNTHETASE INHIBITORS | THE UPJOHN COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| US-4402968-A | Antifungal benzofuranyl imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 1983-09-06 | — | — | US | disclosed |
| EP-0069521-A2 | Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes | THE UPJOHN COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
| US-3927023-A | Imidazolyl benzofurans | WARNER LAMBERT CO | 1975-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | MPO, CAT, LPO | ADRA2A 4280/4885ADRA2B 4159/4885ADRA2C 3415/4885 |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ACHE, CTRL, MMP2 | ADRA2A 2320/4885ADRA2B 2388/4885ADRA2C 2585/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | ADRA2A 2901/4885ADRA2B 2582/4885ADRA2C 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.